Psilocybin Microdose Capsules Ready for Future Clinical Trial

Capsules containing very small doses (microdoses) of psilocybin are ready to be used in a future Nova Mentis clinical trial, with the company one step closer to testing them as a potential treatment for fragile X syndrome. The capsules started being produced per chemistry, manufacturing, and control (CMC)…

Approval Advances Psilocybin Treatment Plans in Canada

Nova Mentis has received the green light from the U.S. Drug Enforcement Administration (DEA) to ship psilocybin (NM-1001) into Canada, moving it a step closer to being tested as a treatment for fragile X syndrome. Psilocybin arrived recently at the labs of the Toronto Institute of Pharmaceutical…